ClinicalTrials.gg
CompletedNCT04923815ST in PSVT-RWSUpdated Feb 23, 2022

A Real-world Study of Cardiac Ablation for PSVT Using ST Catheter

An observational study in AVRT, AVNRT, sponsored by Johnson & Johnson Medical (Shanghai) Ltd.. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by Johnson & Johnson Medical (Shanghai) Ltd. (part of Johnson & Johnson) · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Paroxysmal supraventricular tachycardia known as PSVT includes atrioventricular reentrant tachycardia (AVRT) and atrioventricular nodal reentrant tachycardia (AVNRT).

This study is multicenter, retrospective, cohort study. This study will collect real world data of AVNRT and AVRT cohorts retrospectively to evaluate the effectiveness and safety in real world clinical practice. 300 subjects with PSVT will be consecutively enrolled backwards since 02 Nov 2017, and at least 100 subjects for each cohort.

Cohort one: AVNRT Cohort two: AVRT, including Wolff-Parkinson-White syndrome(WPW)

02

Conditions studied

  • AVRT, AVNRT

Keywords

  • AVRT, AVNRT
03

In context

Lead sponsor

Johnson & Johnson Medical (Shanghai) Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

300 patients with PSVT who meet eligibility criteria and were ablated with ST catheters will be consecutively enrolled backwards since 02 Nov 2017. Two cohorts are atrioventricular reentrant tachycardia (AVRT) and atrioventricular nodal reentrant tachycardia (AVNRT). Each of them contains at least 100 subjects.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Waiver of is approved by Ethics Committee, or follow methods approved by Ethics Committee to get patient's informed consent (such as get informed consent by telephone contact, etc.).
  2. Patients diagnosed as atrioventricular reentrant tachycardia (AVRT), atrioventricular node reentrant tachycardia (AVNRT) after surgery/discharge, and the existing source records must include 1) at least 1 copy of preoperative or intraoperative electrophysiological examination results;2) Information about the acute procedure outcome.
  3. Patients were ablated by ST catheter.
  4. Adult patients 18 years or older.

Exclusion criteria

Exclusion Criteria:

  1. for the use of ST catheters, including:

    1. Ventriculotomy or atriotomy was performed within 8 weeks before the procedure;
    2. Presence of myxoma or intracardiac thrombus;
    3. fitted with artificial valves;
    4. Active systemic infection;
    5. Atrial septal patch.
  2. Pregnant women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (actual)
Patient registry
No

Groups and cohorts

  • AVNRT

    atrioventricular nodal reentrant tachycardia

    Device: THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter

  • AVRT

    atrioventricular reentrant tachycardia, including Wolff-Parkinson-White syndrome(WPW)

    Device: THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter

Interventions

  • DeviceTHERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter

    THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.

06

What researchers measure

Primary outcomes

  1. Acute success rate of PSVT ablation using ST Catheter

    Acute success rate is defined as accessory pathway/slow pathway blockade immediately after ablation, and drug and/or electrophysiological stimulation no longer induces clinical arrhythmias.

    Time frame: Intra-procedure

  2. Incidence of primary adverse events (PAE)

    Primary adverse events include device or procedure related death, myocardial infarction, atrioventricular block, thrombosis, stroke/cerebral vascular accidents (CVA), tamponade/perforation, transient ischemia attack (TIA), pericarditis, major vascular complications/bleeding, Adverse Event which prolonged hospitalization due to non-arrhythmic causes.

    Time frame: From procedure to pre-discharge (an average of 2-3 days)

Secondary outcomes

  1. Acute success rate of cardiac ablation for AVNRT using ST catheter

    defined as accessory pathway blockade, and clinical arrhythmia could not be induced by drug and/or stimulation.

    Time frame: Intra-procedure

  2. Acute success rate of cardiac ablation for AVRT using ST catheter

    defined as slow pathway blockade, and clinical arrhythmia could not be induced by drug and/or stimulation.

    Time frame: Intra-procedure

  3. The proportion of patients who did not develop PSVT recurrence

    Data can be collected from hospital medical records/database and Telephone Survey Questionnaire. Recurrence of PSVT includes recurrence of PSVT identified by electrocardiogram or other cardio-electrical equipment, re-admission due to PSVT, re-procedure due to PSVT, take anti-arrhythmic drug due to PSVT, suffering typical PSVT symptoms.

    Time frame: from discharge to the follow-up visit (an average of 4-6 years)

  4. Incidence of serious adverse events

    Data can be collected from hospital medical records/database and Telephone Survey Questionnaire.

    Time frame: from discharge to the follow-up visit (an average of 4-6 years)

07

Study locations

3 sites
  • Beijing Anzhen hospital, Capital Medical University
    Beijing, Beijing 100029, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266071, China
  • Shanxi Cardiovascular Hospital
    Taiyuan, Shanxi 030024, China
08

References and documents

Individual participant data

Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Data sharing details ↗ · yoda.yale.edu.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Dec 2021, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
Jun 11, 2021
StartActual
Jul 20, 2021
Primary completionActual
Dec 3, 2021
CompletionActual
Dec 14, 2021
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04923815
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Jul 20, 2021
Primary completion
Dec 3, 2021
Completion
Dec 14, 2021
Last update
Feb 23, 2022

Study contacts

Changsheng Ma, Professor
principal investigator · Beijing Anzhen Hospital
Haixiong Wang, Professor
principal investigator · Shanxi Cardiovascular Hospital
Shanglang Cai, Professor
principal investigator · The Affiliated Hospital of Qingdao University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion